Ardsley Advisory Partners LP Acquires New Holdings in Jazz Pharmaceuticals PLC $JAZZ

Ardsley Advisory Partners LP acquired a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 50,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,500,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in JAZZ. Hilltop National Bank bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at approximately $36,000. LRI Investments LLC bought a new position in Jazz Pharmaceuticals in the 4th quarter valued at approximately $38,000. Danske Bank A S bought a new position in shares of Jazz Pharmaceuticals during the third quarter valued at $40,000. Geneos Wealth Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Jazz Pharmaceuticals by 1,383.3% during the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 332 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz announced a major research collaboration and licensing deal with AbCellera to discover and develop next-generation T-cell engaging multispecific antibodies for cancer, including solid tumors. The agreement could be worth up to roughly $820 million to $876 million per drug if milestones are achieved, signaling a potentially meaningful new pipeline opportunity. Article: Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
• Positive Sentiment: Jazz also released extensive late-breaking data at SLEEP 2026 showing real-world benefits of Xywav in narcolepsy and idiopathic hypersomnia, including evidence of improved patient outcomes and possible cardiometabolic benefits linked to reduced sodium exposure. That supports the company’s commercial franchise and may reinforce confidence in a core revenue driver. Article: Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026
• Neutral Sentiment: A director disclosed a planned sale of 1,157 shares under a pre-arranged 10b5-1 trading plan. While insider selling can sometimes attract attention, the small size and scheduled nature make it unlikely to be a major fundamental concern. Article: SEC filing for director sale

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $226.93 on Thursday. Jazz Pharmaceuticals PLC has a twelve month low of $105.00 and a twelve month high of $243.32. The firm has a fifty day simple moving average of $220.08 and a 200 day simple moving average of $189.96. The company has a market capitalization of $14.26 billion, a PE ratio of -11,340.83, a P/E/G ratio of 0.20 and a beta of 0.32. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The business had revenue of $1.07 billion during the quarter. On average, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on JAZZ. UBS Group raised shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the company from $188.00 to $307.00 in a research note on Tuesday, May 19th. Robert W. Baird set a $252.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. TD Cowen raised their price target on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Barclays raised their price target on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. Finally, Weiss Ratings downgraded shares of Jazz Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, June 12th. Sixteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $246.06.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total transaction of $278,196.00. Following the transaction, the executive vice president directly owned 51,549 shares in the company, valued at approximately $11,950,604.67. The trade was a 2.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark Douglas Smith sold 1,157 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $230.55, for a total transaction of $266,746.35. Following the completion of the transaction, the director owned 9,680 shares in the company, valued at approximately $2,231,724. The trade was a 10.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,098 shares of company stock valued at $2,832,086. 4.10% of the stock is owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.